Dopamine, as well as norepinephrine, is a link between noradrenergic nerve terminals and splenocytes.
The effect of supramaximal electric field stimulation on 3H released from rat spleen strips was studied after loading with either [3H]dopamine ([3H]DA) or [3H]norepinephrine ([3H]NE). In some experiments, [3H]DA and [3H]NE stored in the tissue or released in response to electrical stimulation were separated from their tritiated metabolites using HPLC followed by radiochemical detection. The stimulation-evoked release of 3H after loading with either derivative was subject to negative feedback modulation through alpha2-adrenergic, D2-dopamine and muscarinic acetylcholine receptors, and could be prevented by either calcium removal or tetrodotoxin blocking of Na+ influx, indicating its neuronal and vesicular origin. After the separation of radioactive metabolites by HPLC, both the tissue loaded with [3H]DA and the fractions collected during electrical stimulation contained a considerable amount of [3H]NE, providing evidence that the neurons it originated from were adrenergic in function. [3H]DA was also released during electrical stimulation. Since the spleen does not receive dopaminergic innervation, it was concluded that the noradrenergic axon terminals in the spleen were able to take up DA, convert it in part into NE, and release it as both DA and NE in response to neural activity. The ratio of [3H]DA and [3H]NE in the spleen loaded with [3H]DA was found to be dependent on both temperature and time of loading, and could be modulated by various drugs such as desmethylimipramine, a NE uptake blocker, and disulfiram or fusaric acid, dopamine beta-hydroxylase inhibitors. The phenomenon may reveal a new mechanism by which immunocytes in the spleen can be regulated by the neuroendocrine system.
Bencsics
A
A
Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest.
Sershen
H
H
Baranyi
M
M
Hashim
A
A
Lajtha
A
A
Vizi
E S
ES
D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D001599:Berberine / Q000031:analogs & derivatives / Q000494:pharmacology; D003000:Clonidine / Q000494:pharmacology; D003891:Desipramine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D004558:Electric Stimulation; D008297:Male; D018721:Muscarinic Agonists / Q000494:pharmacology; D009638:Norepinephrine / Q000096:biosynthesis / Q000494:pharmacology*; D010095:Oxotremorine / Q000494:pharmacology; D017729:Presynaptic Terminals / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen / Q000166:cytology / Q000294:innervation*; D013469:Sulpiride / Q000494:pharmacology; D013566:Sympathomimetics / Q000378:metabolism / Q000494:pharmacology*; D014316:Tritium
D018759:Adrenergic Uptake Inhibitors; D000316:Adrenergic alpha-Agonists; D018492:Dopamine Antagonists; D018721:Muscarinic Agonists; D013566:Sympathomimetics; D001599:Berberine; D014316:Tritium; C048886:7,8-(methylenedioxy)-14-hydroxyberbane; D010095:Oxotremorine; D013469:Sulpiride; D003000:Clonidine; D003891:Desipramine; D004298:Dopamine; D009638:Norepinephrine